Tag: #guidance

Corporate Earnings

CoreWeave Shares Surge 25% After Blowout Earnings and Upbeat Guidance Ease AI Funding Fears

Thursday, November 12, 2026 | 00:02

CoreWeave shares surged nearly 25% on Wednesday, marking the neocloud company’s best single-day performance since April 2025, after a stellar third-quarter earnings report easily surpassed Wall Street expectations and the company raised its full-year guidance. The dramatic market rally offered a much-needed psychological boost to the artificial intelligence infrastructure sector, which had faced intense scrutiny […]

Corporate Earnings

CoreWeave Reports Soaring Revenue and Raises 2026 Guidance Despite Market Headwinds and Financing Pressures

Wednesday, November 11, 2026 | 00:02

CoreWeave Inc. reported better-than-expected quarterly revenue and raised its full-year 2026 guidance, offering a reassuring signal that underlying demand for artificial intelligence infrastructure remains robust despite mounting concerns over a broader market slowdown. The announcement, delivered on Tuesday, helped drive the company’s stock higher in extended trading, providing a temporary reprieve during a challenging period […]

Corporate Earnings

Figma Shares Tumble Despite Strong Third-Quarter Earnings and Raised Full-Year Guidance

Tuesday, November 10, 2026 | 09:37

Figma signage is displayed prominently at the New York Stock Exchange in New York as the major design software company prepares for its shares to begin trading on July 31, 2025. The high-profile debut brought intense market scrutiny to the cloud-based design platform, setting the stage for its subsequent quarterly disclosures and financial performance metrics. […]

Corporate Earnings

Rheinmetall Cuts Full-Year Guidance Amid Contract Delays, Sending Shares Plunging

Sunday, November 8, 2026 | 00:02

German defense giant Rheinmetall has cut its full-year financial guidance late Wednesday, pointing to persistent delays in crucial military contracts and artillery ammunition deliveries. The announcement marks the company’s second outlook reduction since August, when broader geopolitical and domestic procurement shifts began weighing on the industrial titan. The revised forecast underscores the operational hurdles facing […]

Corporate Earnings

Eli Lilly Raises Full-Year Guidance as Zepbound and Mounjaro Demand Drives Blowout Third-Quarter Results

Thursday, October 29, 2026 | 12:02

Eli Lilly reported third-quarter earnings and revenue on Thursday that easily surpassed Wall Street’s consensus expectations, driven by surging international and domestic demand for its blockbuster weight-loss medication Zepbound and its leading-edge diabetes treatment Mounjaro. Reflecting this sustained commercial momentum, the pharmaceutical giant dramatically increased its full-year financial outlook for revenue, even as it navigates […]